Teva Pharmaceutical Industries Limited Ordinary Shares
TEVA · NYSE
Analyst Consensus
Analyst Ratings Synthesis
Consensus is Buy across 12 analysts, with a stated mean price target of $40. The supplied consensus does not report a low or high target, so the target cluster and spread cannot be measured, and it does not identify the most or least bullish analyst. No named analyst rating or price-target revisions are explicitly reported during the week. The research instead shows a substantive operating debate: innovative-drug growth and a raised 2026 revenue outlook support the bullish case, while the second-quarter earnings miss, Emalex acquisition costs and lower generic Revlimid sales support caution. The available evidence does not establish whether analyst disagreement over those issues caused any target dispersion.
Rating Actions
No individual rating actions have been captured for TEVAyet. Consensus figures above come from Nasdaq's aggregate feed.
